Dr. Emad Rizk Joins Accuray Board of Directors
SUNNYVALE, Calif., March 28, 2013 – Accuray Incorporated (Nasdaq: ARAY), announced today the appointment of Emad Rizk, M.D. to the company’s Board of Directors, effective March 15, 2013.
Dr. Rizk is a renowned healthcare industry expert who brings more than 25 years of experience working with payers, hospital systems, government, physicians and pharmaceutical companies to the Accuray board of directors. Since 2003, he has served as president of McKesson Health Solutions, a business unit of McKesson Corporation that delivers industry-leading clinical evidence and expert technology to help Payers and Providers collaborate for better healthcare outcomes at lower costs. Prior to joining McKesson, Dr. Rizk served as Senior Partner and Global Director of Deloitte Consulting, where he led medical cost and quality management across segments.
“We are pleased to welcome Dr. Rizk to the board of directors of Accuray. Dr. Rizk’s extensive leadership experience, strong track record of growth and intimate understanding of the needs and concerns of all healthcare industry stakeholders, make him a vital addition to the board,” said Joshua H. Levine, president and chief executive officer of Accuray.
“I am delighted to join Accuray’s board of directors” said Dr. Rizk. “Accuray’s advanced radiation therapy technologies, the CyberKnife and TomoTherapy Systems are perfect examples of how innovative medical technology enables hospitals and physicians to deliver superior, efficient and cost-effective patient care.”
In 2011, Modern Physician named Dr. Rizk as one of the nation’s “50 Most Influential Physician Executives” for the fourth year in a row. He has also been listed among the “Top 100 Most Powerful People in Healthcare” by Modern Healthcare and named one of the nation’s “Top 25 Leaders in Disease Management” by Managed Healthcare Executive. Dr. Rizk has an extensive portfolio of published journal articles and books including The New Era of Healthcare: Practical Strategies for Providers and Payers. He’s has served on several healthcare boards including the National Clinical Advisory Board and UM Advisory Council. Dr. Rizk currently serves on the boards of DMAA: Care Continuum Alliance, National Association for Hispanic Health, University of North Texas, National Quality Review and Managed Care Magazine. He is a lecturer at Wharton, Harvard, MIT, Columbia, and Kellogg.
Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that develops, manufactures and sells personalized, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company’s leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the anticipated contributions of a new board member. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading “Risk Factors” in the company’s report on Form 10-K filed on September 10, 2012, as updated in our Form 10-Qs filed on November 8, 2012 & February 6, 2013, and as updated periodically by our other filings. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.